Kleo Brings Small-Molecule Approach To IO With Three Technological Applications
Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.
You may also be interested in...
Amgen sees the approval as a platform to expand blinatumomab into other hematologic malignancies using similar approaches.
Emergent reveals acquisition of GSK's anthrax therapy raxibacumab days after a vaccine deal with Sanofi. Telix licenses PSMA antibodies from Abzena, while PeptiDream and Kleo sign an immuno-oncology pact.
With a focus on specialty drugs, Bristol wants to be known for more than immuno-oncology. To that end, specialty development head Douglas Manion is charged with leading innovation in immunology, virology and cardiovascular, genetically defined and fibrotic disease.